News

Novo Nordisk A/S: Tresiba® (insulin degludec) approved in Japan (28 September 2012)

Read the full announcement in pdf format

Novo Nordisk today announced that the Japanese Ministry of Health, Labour and Welfare has approved Tresiba® (insulin degludec) for the treatment of diabetes.

Media:
Investors:
Mike Rulis Kasper Roseeuw Poulsen
Tel: (+45) 3079 3573 Tel: (+45) 4442 4303
mike@novonordisk.com krop@novonordisk.com
Frank Daniel Mersebach
Tel: (+45) 4442 0604
fdni@novonordisk.com
Lars Borup Jacobsen
Tel: (+45) 3075 3479
lbpj@novonordisk.com
In North America:
Ken Inchausti Jannick Lindegaard
Tel: (+1) 609 514 8316 Tel: (+1) 609 786 4575
kiau@novonordisk.com jlis@novonordisk.com

Company Announcement No 59 / 2012

  •  
Search for Danish versions and earlier news releases:

Language
Year
Month
Type
Search for:

Search
  •  
  •  

Sign up for the latest news from Novo Nordisk

SMS/e-mail

Twitter

Facebook

RSS feeds

 
  •  
  •  
Pipeline
  •  
  •  
Click here to go to the download centre to download presenations, reports or magazines
  •